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Direct Percutaneous Left Ventricular Access
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Pre-Clinical Feasibility
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Objectives This study sought to evaluate feasibility of nonsurgical transthoracic catheter-based left
ventricular (LV) access and closure.
Background Implanting large devices, such as mitral or aortic valve prostheses, into the heart re-
quires surgical exposure and repair. Reliable percutaneous direct transthoracic LV access and closure
would allow new nonsurgical therapeutic procedures.
Methods Percutaneous direct LV access was performed in 19 swine using real-time magnetic reso-
nance imaging (MRI) and an “active” MRI needle antenna to deliver an 18-F introducer sheath. The
LV access ports were closed percutaneously using a commercial ventricular septal defect occluder
and an “active” MRI delivery cable for enhanced visibility. We used “permissive pericardial tampon-
ade” (temporary ﬂuid instillation to separate the 2 pericardial layers) to avoid pericardial entrapment
by the epicardial disk. Techniques were developed in 8 animals, and 11 more were followed up to
3 months by MRI and histopathology.
Results Imaging guidance allowed 18-F sheath access and closure with appropriate positioning of
the occluder inside the transmyocardial tunnel. Of the survival cohort, immediate hemostasis was
achieved in 8 of 11 patients. Failure modes included pericardial entrapment by the epicardial oc-
cluder disk (n  2) and a true-apex entry site that prevented hemostatic apposition of the endocar-
dial disk (n  1). Reactive pericardial effusion (192  118 ml) accumulated 5  1 days after the pro-
cedure, requiring 1-time drainage. At 3 months, LV function was preserved, and the device was
endothelialized.
Conclusions Direct percutaneous LV access and closure is feasible using real-time MRI. A commer-
cial occluder achieved hemostasis without evident deleterious effects on the LV. Having established
the concept, further clinical development of this approach appears realistic. (J Am Coll Cardiol Intv
2011;4:1318–25) © 2011 by the American College of Cardiology Foundation
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1319Safe and reliable direct percutaneous access and closure of
left ventricular (LV) access ports would enable a range of
cardiac and vascular interventions currently feasible only
with surgery. These might include percutaneous transapical
aortic valve replacement (1–3), mitral valve repair and replacement
(4,5), and retrograde aortic root endograft procedures (6).
Direct LV access risks injury to critical structures, includ-
ing the ventricular septum (7) or coronary arteries (8) and
requires immediate recognition of procedural complications,
including pericardial tamponade or hemothorax (9). Real-
time magnetic resonance imaging (MRI) depicts blood and
cardiac soft tissue in a larger thoracic context, making it an
attractive tool to guide interventional procedures (10,11).
We hypothesized that real-time MRI could guide large
percutaneous LV access port placement in a closed-chest,
beating heart procedure and, thereafter, closure of the
myocardial access port without surgery.
Methods
Animals. Animal procedures were conducted according to
ontemporary National Institutes of Health guidelines, in
9 naive Yorkshire swine (43  9 kg). Eight animals were
sed for technique development and 11 were kept alive and
ssigned to up to 3 months of follow-up. Animals were
re-treated with aspirin and amiodarone. Anesthesia was
aintained with inhaled isoflurane and mechanical
entilation.
Before LV access, a subxiphoid pericardial drainage
atheter (8.3-F, Boston Scientific, Natick, Massachusetts)
as placed under x-ray fluoroscopy, and the femoral artery
nd vein were accessed percutaneously for monitoring (12).
Active interventional equipment. For cardiac puncture, an
18-gauge, MRI-compatible (nickel-titanium-chromium) nee-
dle was customized for “active profiling” (visibility along its
entire length during MRI) by integrating a loop coil along the
needle shaft. Characteristic spacing between needle marker
coils assisted in distinguishing the needle shaft from the tip.
The LV puncture site was closed with a commercial
6-mm muscular ventricular septal defect (VSD) occluder
(AGA Medical, Plymouth, Minnesota). Unmodified de-
vices were used in initial technique development, and
modified devices (replacing the microscrew stainless steel
with titanium to minimize MRI artifacts) (Fig. 1) were
implanted in the survival cohort.
A custom delivery cable for the VSD occluder was
developed to enhance visibility and reduce MRI artifacts. It
incorporated a loopless antenna and had its steel mating
microscrew replaced with titanium. The antenna was tuned
so that MRI signal was maximal when the attached occluder
achieved the fully deployed state before release.
Active devices were connected to a separate MRI receiver
channel, and a device-related signal was independently
colored and overlaid on real-time images (13).Percutaneous LV access. All procedures were performed
under real-time MRI guidance, with multiple continuously
updated slices (Fig. 2).
An apical puncture trajectory was selected in consider-
ation of the following: 1) avoiding bony structures of the
chest; 2) the shortest distance to the heart; 3) avoiding
coronary arteries; 4) the desired LV needle entry target,
whether apical or para-apical; 5) avoiding injury to intra-
cavitary structures (papillary muscles and interventricular
septum); and 6) further intracavitary trajectories toward
aortic or mitral valve structures.
An “active” 18-gauge needle was advanced from a se-
lected thoracic skin location and, based on the position of
the needle microcoils, the final trajectory was planned, and
the needle was advanced into the LV cavity. An 18-F sheath
(Cook Medical, Bloomington, Indiana) was delivered over a
0.035-inch Nitrex guidewire (ev3, Plymouth, Minnesota).
A second, backup nitinol guidewire was also positioned
alongside the sheath.
Heparin was administered to achieve an activated clotting
time 250 s immediately following sheath placement and
during and after closure to
“stress” the test of immediate
hemostasis.
Percutaneous LV closure. Percu-
aneous LV closure was per-
ormed with the muscular VSD
ccluder, under real-time MRI
uidance. In an effort to avoid
ericardial entrapment by the
ccluder, saline was instilled into
he pericardial space guided by
eal-time MRI immediately be-
ore device deployment temporarily to separate the 2 peri-
ardial layers (“permissive pericardial tamponade”) (12).
6-mm VSD occluder was deployed using standard
Abbreviations
and Acronyms
CT  computed tomography
IQR  interquartile range
LV  left ventricle
MRI  magnetic resonance
imaging
VSD  ventricular septal
defect
Figure 1. Ex Vivo MRI of Muscular VSD Occluder
(A) Off-the-shelf occluder with stainless steel screw creating imaging arti-
fact. (B) A similar device after replacement of the device screw to a tita-
nium screw. The device itself is made of nitinol mesh, which is passively
visualized on MRI but without signiﬁcant artifact. MRI  magnetic reso-
nance imaging; VSD  ventricular septal defect.
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1320techniques (14). Finally, the instilled pericardial fluid was
aspirated.
Magnetic resonance imaging. Interventions were performed
n a 1.5-T MRI scanner (Espree, Siemens, Erlangen, Germany)
sing standard surface body receive coils. The wide (70-cm)
ore allows operator access to the chest of large animals that
e predict would translate to patients. MRI was used to
uide all interventional procedures and for geometry and
unction measurements of the LV, pleural and pericardial
uid assessment, and myocardial scar.
For interventional procedures, we used real-time bal-
nced steady state free precession (repetition time/echo
ime: 3.67/1.23 ms; flip angle: 45°; field of view: 340  255
m; matrix: 192  144 pixels; slice thickness: 6 mm; and
andwidth: 789 Hz/pixel; parallel imaging and undersam-
ling provided 3 to 5 frames/s). Images were reconstructed
nd displayed to the operator on a separate real-time
orkstation (13).
Cardiac computed tomography (CT) angiography roadmaps
coregistered with real-time MRI. To avoid coronary artery
njury, we used a cardiac CT angiography-derived
-dimensional road map of the coronary tree overlaid on the
Figure 2. Real-Time MRI During LV Access
Real-time magnetic resonance imaging (MRI)-delineated 3-dimensional trajecto
ing planes for needle guidance (A,B), 1 short-axis plane for monitoring left ve
ing for these 3 planes (D). The dotted yellow line in A and B insets indicate
continuously as the needle is advanced toward the heart. Needle markers areeal-time MRI.Electrocardiogram-gated cardiac CT angiography was
erformed in a nonspiral mode on a 320-slice CT scanner
Aquilion ONE, Toshiba Medical Systems, Tokyo, Japan)
sing 16-cm detector coverage, 100-kV tube voltage,
50-mA tube current, and 350-ms gantry rotation time.
he CT surface model and MRIs were manually registered
o each other using anatomic landmarks, such as the aortic
rch and coronary ostia (3D Slicer, Slicer.org, Brigham and
omen’s Hospital, Boston, Massachusetts). After registra-
ion to the MRI volume, the coronary volume was imported
nto the real-time workstation (IFE, Siemens Corporate
esearch, Princeton, New Jersey) as a 3-dimensional surface
verlaid on the real-time MRI images (Fig. 3C).
Follow-up. After closure, animals were observed for 3 h by
serial hemodynamics and MRI, with attention to pericardial
and pleural fluid, and by radiocontrast angiography. Serum
and pericardial hematocrit and (human) cardiac troponin I
(i-STAT, Abbott, Princeton, New Jersey) were measured.
Follow-up was pre-specified for days 1 to 3 and 5 and
weeks 4 and 12 and included MRI to evaluate device
position, LV function, myocardial scar, and pericardial and
pleural fluid volume. Euthanasia at pre-specified time points
the active needle by continuously updating 2 perpendicular long-axis imag-
ar (LV) function (C), and a 3-dimensional representation of relative position-
ctory plan for potential aortic valve intervention. This trajectory is updated
t throughout the procedure (arrowheads). Also see Online Video 1.ry for
ntricul
a traje
evidenallowed necropsy samples at weeks 1, 4, and 12.
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1321Pathology. Necropsy examination of the heart, pericardium,
and muscular VSD occluder was performed in all. Histological
analysis was performed 3 months after the procedure. Sections
were examined by light microscopy for the presence of inflam-
mation, thrombus, neointimal formation, and injury following
toluidine blue and basic fuchsin staining.
Data analysis. Statistical analysis used GraphPad Software,
a Jolla, California). Numerical parameters are reported as
ean  SD or median (interquartile range) as appropriate.
ontinuous repeated parameters were tested using analysis
f variance, 2-tailed paired t test, or Wilcoxon matched-
airs signed-rank test, as appropriate, and p  0.05 was
onsidered significant.
esults
Initial feasibility of percutaneous access and closure of LV. The
technique was developed in 8 animals that were sacrificed; 3
underwent only percutaneous LV access and 5 underwent
both access and closure. During these experiments, 1 case of
septal injury by the 18-F sheath was attributed to an excessively
soft 0.035-inch guidewire that was replaced with a stiff one in
later experiments. In another case, the occluder was withdrawn
from the myocardial hole due to accidental retraction. There-
after, experiments used a backup wire to prevent this compli-
cation, although it was never required thereafter.
Safe and targeted percutaneous LV access achieved with
real-time MRI guidance. Eleven animals had percutaneous
LV access and closures guided by real-time MRI and were
kept alive up to 3 months. The use of an active needle
enabled clear visualization of the device in relation to soft
tissues along the needle trajectory (Fig. 2) from skin
puncture to LV cavity entry. This allowed selection of an
optimal puncture site for potential future aortic or mitral
access while avoiding injury to papillary muscles, interven-
tricular septum, or mitral valve structures (Figs. 3A and 3B,
Online Video 1). Coregistration of coronary CT angiography
assured the operator that the needle would not injure a
coronary artery (Fig. 3C). Follow-up coronary angiograms
verified intact coronary arteries in all.
Left ventricular puncture and sheath placement provoked
isolated premature ventricular contractions but no sustained
arrhythmia. Heart rate (100  19 vs. 100  16 beats/min,
espectively) and systolic arterial blood pressure (75  7 vs.
9  11 mm Hg, respectively) remained unchanged from
aseline to puncture and 18-F sheath delivery (Figs. 4A and
B). Left ventricular puncture and 18-F sheath placement
aused minor pericardial hemorrhage (30  26 ml).
The time required to access the LV and introduce an
8-F sheath was 29  9 min. The 18-F sheath remained
nside the LV for 29  9 min.
Early effects of muscular VSD occluder-mediated closure of
apical access site. In all animals (n 11), the occluder deviceFigure 3. Cardiac Structures To Avoid During Percutaneous LV Access
Real-time procedural MRI enabled the operator to avoid injury to cardiac struc-
tures, such as (A) papillary muscles, (B) interventricular septum, and (C) coronary
arteries. In C, a 3-dimensional coronary artery image (red structures) is coregistered
with real-time MRI during puncture. LAD  left anterior descending; LCX  leftas successfully deployed inside the LV wall puncture tract.
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1322Real-time MRI depicted the distal (“endocardial”) and proxi-
mal (“epicardial”) disk deployment (Figs. 5A and 5B) with
espect to the cardiac structures and LV free wall, enabling the
perator to perform safe device deployment (Online Video 2).
During device deployment, “permissive pericardial tam-
onade” was temporarily induced to separate visceral and
arietal pericardium by instilling 213  76 ml of saline into
he pericardial space under real-time MRI guidance. This
echnique efficiently separated the 2 pericardial layers (Figs.
A and 5B) in 8 of 11 cases with transient 42  10 mm Hg
57  13%) decrease in systolic blood pressure from
aseline. During the exchange of the 18-F sheath and
ccluder device deployment, 149  246 ml of blood also
ccumulated in the pericardial space. Immediately following
evice deployment, all pericardial fluid was aspirated (total
f 363  283 ml) with stabilization of the systolic arterial
lood pressure (73  12 mm Hg) compared with baseline
79  11 mm Hg) (Fig. 4B, Online Video 2). Left
entricular closure was accomplished in 15  8 min.
During the 3-h post-procedure observation period, ani-
als were hemodynamically stable (Fig. 4). X-ray ventricu-
ography and serial MRI indicated no shift in device
osition or contrast extravasation (Figs. 5C and 5D).
A total of 9 5 ml of fluid accumulated in the pericardial
pace (pericardial fluid hematocrit of 4  2%) during the
Figure 4. Hemodynamics, LV Function, and Serum Hematocrit Values Durin
(A,B) Hemodynamics remained stable throughout the procedure. During closu
heart rate tended to increase (A) (p  0.18), whereas arterial blood pressure r
the procedure and trended downward after 5 days (p  0.39 vs. baseline). (D)
dure. BPM  beats/min.-h observation without a change in serum hematocritFig. 4C). As expected during myocardial traversal, cardiac
roponin I levels increased from 0 (interquartile range
IQR]: 0 to 0.04) at baseline to 0.39 (IQR: 0.2 to 0.9) ng/ml
t 3 h (p  0.004).
All animals had early (day 5  1) pericardial fluid
accumulation. Because it was not feasible to leave a post-
procedure pericardial drain in these animals, a single peri-
cardiocentesis was performed on day 5  1 to aspirate
192  118 ml of fluid (hematocrit 2%). Thereafter, no
urther pericardial or pleural fluid accumulated in animals
ith appropriately positioned devices.
Complications associated with percutaneous closure.
Within the survival animal cohort (n  11), immediately
after device deployment, 2 animals had bloody right pleural
effusion that was drained and did not recur.
In 3 of 11 survival animals, the pericardium was entrapped
by the “epicardial” occluder disk. This “tethered” open the LV
access tract, resulting in tamponade and early death in 2 and
nonlethal late pericardial effusion at 1 month in the third.
A third animal died early because the selected puncture site
was the true apex. In this animal, the “endocardial disk” was
deformed dynamically by the contracting apical myocardium,
preventing effective hemostasis of the LV access port.
Late evaluation of apical access port after percutaneous
closure. Of the surviving animals (n  8), 2 were kept alive
cutaneous Direct Access and Closure of the LV
the left ventricle (LV) and following “permissive pericardial tamponade,” the
ed unchanged (B) (p  0.87). (C) Serum hematocrit remained stable during
der device closure had no effect on LV function early or late after the proce-g Per
re of
emain
Occlufor 1 week, 4 for 1 month, and 2 for 3 months. As
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1323represented in Figure 4D, percutaneous LV access and
subsequent closure did not adversely affect LV function.
Baseline LV ejection fraction (0.40  0.07) did not change
arly (0.43  0.07 at 2 days) or late (0.39  0.05 at 1
onth, and 0.48 0.05 at 3 months) after the procedure.
No LV myocardial fibrosis developed beyond the access
ite as evaluated by delayed gadolinium enhancement MRI
tudies at follow-up. No pleural effusion accumulated dur-
ng the follow-up period.
Pathology. Macroscopic pathological evaluation at weeks
1, 4, and 12 indicated that the device remained inside the
puncture tract (Fig. 6). No intracavitary LV thrombus
was found.
The epicardial disk was deployed appropriately inside the
pericardial space in 12 of 15 animals. In 3 animals from the
survival cohort, the epicardial disk entrapped the parietal
pericardium.
Histology examination at 3 months showed that both
occluder disks were well opposed to the endo- and epicardial
surfaces of the ventricle. The endocardial surface was fully
Figure 5. Muscular VSD Occluder Deployment Inside Myocardial Puncture
(A,B) “Permissive pericardial tamponade” separated the parietal from the visce
cardial space”). (A) The “endocardial” (distal) disk (arrowhead) is released insid
is the active delivery cable (“cable”) and back-up guidewire (“wire”). (B) The “e
entrapping the pericardium. Also see Online Video 2. (C) Early x-ray ventriculo
leakage, and (D) MRI veriﬁed the correct position of the device inside the myo
tions as in Figures 1 and 2.endothelialized with no surface thrombus formation. Theepicardial retention disk was fully incorporated with well-
organized smooth muscle growth, moderate angiogenesis,
and moderate-to-severe inflammatory cells. All inflamma-
tory reaction was contained within or in close proximity to
the device. Overall, there was occlusive infiltration of the
muscular VSD occluder with rich proteoglycan matrix,
smooth muscle cells, angiogenesis, and chronic inflamma-
tory cells.
Discussion
We describe a novel approach for percutaneous closed-chest
direct transthoracic access to the beating heart using large
devices intended for structural heart therapies. Real-time
MRI is a powerful tool for accurately guiding the interven-
tional procedure, by providing instantaneous display of the
entire thoracic context and cardiac target to the operator.
As structural heart disease therapies become more sophis-
ticated, direct transapical perventricular access options be-
come more important. A large minority of patients under-
Guided by Real-Time MRI
ricardium by temporary instillation of ﬂuid into the pericardial space (“peri-
LV cavity in proximity to the endocardial surface. Also visible in this image
ial” (proximal) disk was released against the epicardium (arrow) without
y showed occlusion of the puncture tract without extraventricular contrast
l tract (black, indicated by the arrow) in a dark-blood acquisition. Abbrevia-Tract
ral pe
e the
picard
graph
cardiagoing transcatheter aortic valve replacement require
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1324transapical access because of iliofemoral arteries that are
small, tortuous, calcified, or occluded (15). Transapical
access is often required for percutaneous repair of paraval-
vular regurgitation (4) and could enable transcatheter im-
plantation of large mitral valve prostheses (5). Percutaneous,
closed-chest, direct LV access would be an attractive alter-
native to the current practice of open-chest, surgical transapical
approach, which is associated with morbidity and prolonged
hospitalization (1).
Procedural failures in the present study were primarily
due to unfamiliar technique during early development and
use of an occluder device purpose-built for a different
application. This limitation should not detract from the
important finding that large operative appliances could be
introduced and removed from the heart without surgical
exposure. Furthermore, 3-month follow-up of LV function
and histology demonstrated the safety and durability of the
device in the LV free wall.
Design implications. The double-disk occluder design ap-
ears to anchor sufficiently during deployment and during
ealing, and it appears to accommodate the contracting
yocardium. However, the commercial muscular VSD
losure device was not designed for this application. Its
orosity (16) may contribute to early bleeding, its neck
ength is fixed, and its pliable disks distort and malappose
uring cardiac contraction in a true apical position. These
roblems are surmountable with device customization to
educe porosity (e.g., with a surface membrane [17]) and to
etter conform to tract geometry. We predict this approach
Figure 6. Pathological Evaluation of VSD Occluder Inside the
LV Free Wall Myocardium
Low power image of the toluidine blue and basic fuchsin stain of the
muscular VSD occluder inside the sealed myocardial access tract. Note
microscopic traction of healthy myocardium over the lateral aspect of
the endocardial disk by ﬁbrosis. Abbreviations as in Figures 1 and 2.ould scale into larger devices.Our experience suggests that pericardial entrapment by
he LV closure device may result in early or late bleeding
ue to the cyclic discordant motion of the 2 pericardial
ayers, leading to continuous movement of the device inside
he transmyocardial tunnel. Our technique of “permissive
amponade” failed to ensure intrapericardial deployment of
he outer disk in one-fifth of cases. Enhanced sheath
esigns (outer balloons, expandable meshes) may help to
isplace the parietal pericardium from the epicardium and
o improve reliability. Pericardial displacement appears nei-
her feasible nor necessary in cases of pericardial adhesion or
bsence, for example, after transmural infarction or cardiac
urgery, because there is no discordant pericardial motion
ausing device distortion or displacement (data not shown).
The early nonrecurrent accumulation of serosanguinous
ericardial fluid probably represent reactive pericardial effu-
ion to the epicardial disk. In patients, this would be
anaged using temporary drains, as in surgical patients.
Alternative closure considerations. Small LV access ports
6-F) have been allowed to close spontaneously (18,19)
nd more recently have been closed in animals using
ascular closure staples (20) and in humans using vascular
mbolization coils (4). These techniques are less attractive
pplied to larger access ports.
The current surgical standard to close left ventricular access
ites is to apply 1 or more transmural pledgeted purse-string
pical sutures after minithoracotomy exposure (1). Suture-
ased catheter devices are under development to recapitulate
his approach.
Finally, device solutions must also accommodate hetero-
eneity of target myocardial wall thickness identified during
re-procedure imaging, including mixed transmural and
ontransmural myocardial infarction and hypertrophy.
Imaging guidance. Direct percutaneous LV access and clo-
sure requires instantaneous soft tissue imaging to identify
anatomic structures and bleeding complications. The pres-
ent study supports the use of real-time MRI for this
application. However, alternative image guidance options
exist. Biplane x-ray fluoroscopy combined with intrapericar-
dial radiocontrast might outline epicardial targets, but they
do not allow trajectory planning, thereby risking injuries to
mitral subvalvular or other cardiac structures (7,8), nor moni-
toring for tract hemorrhage. Three-dimensional ultrasound is
limited by available imaging windows and context, but intra-
cavitary 3-dimensional ultrasound continues to evolve (21).
Roadmaps, such as 3-dimensional reconstructed rotational
angiograms (22) or cardiac MRI (23) overlaid on biplane x-ray
fluoroscopy allow trajectory planning. We found CT-derived
roadmaps helpful to ensure that needle trajectories avoided
coronary arteries. However, roadmaps risk misregistration
especially from alterations in loading conditions and displaced
tissue, and they do not represent “live” data during, for
example, rapidly evolving complications. Jelnin et al. (24)
recently reported percutaneous direct left ventricular access in
m
e
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1325post-surgical patients using CT-derived roadmaps, and closure
of smaller 5-12Fr holes using similar nitinol devices.
Conclusions
We believe this experience establishes the concept that with
suitable devices and suitable imaging guidance, large cardiac
access ports can be introduced and sealed without surgical
exposure. Custom closure devices will improve the perfor-
mance and reliability of this approach.
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APPENDIXFor accompanying videos, please see the online version of this article.
